Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung …

C Bergonzini, A Leonetti, M Tiseo… - Expert opinion on …, 2020 - Taylor & Francis
Introduction Non-small cell lung cancer (NSCLC) is a highly lethal disease. During the past
20 years, the epidermal growth factor receptor (EGFR) has been a relevant target for …

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs

S Watanabe, Y Goto, H Yasuda, T Kohno… - Thoracic …, 2021 - Wiley Online Library
Background Patients with non‐small cell lung cancer (NSCLC) harboring activating EGFR
mutations are sensitive to epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR …

[PDF][PDF] Different EGF-induced receptor dimer conformations for signaling and internalization

J Haubrich, JM Zwier, F Charrier-Savournin, L Prézeau… - 2024 - repository.ubn.ru.nl
The structural basis of the activation and internalization of EGF receptors (EGFR) is still a
matter of debate despite the importance of this target in cancer treatment. Whether agonists …

Different conformations of EGF-induced receptor dimers involved in signaling and internalization

J Haubrich, JM Zwier, F Charrier-Savournin, L Prézeau… - bioRxiv, 2022 - biorxiv.org
The structural basis of the activation of EGF receptors (EGFR) is still a matter of debate
despite the importance of this target in cancer treatment. Whether agonists induce dimer …

Conformational dynamics and pharmacology in transmembrane dimeric receptors

J Haubrich - 2021 - theses.hal.science
Transmembrane receptors are proteins that translate extracellular information into
intracellular signals. These proteins are categorised based on the way they transduce …

[PDF][PDF] An HSP90 inhibitor overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs

渡辺翔, ワタナベショウ - Thoracic Cancer, 2021 - ir.jikei.ac.jp
Background: Patients with non-small cell lung cancer (NSCLC) harboring activating EGFR
mutations are sensitive to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR …